0 rating

Acute Leukemia

Chen WL, Wang JH, Zhao AH et al.

Shanghai Jiao Tong University, Shanghai, China.

 Blood 2014;124:1645–54.

Rob Sellar’s review: Abnormalities of glucose metabolism, including of glycolysis and the tricarboxylic acid (TCA) cycle, have been found in cancer cells and linked to both treatment resistance and clinical outcome. In acute myeloid leukemia (AML), an intermediate metabolite of the TCA cycle, 2-hydroxyglutarate (2-HG), is produced by mutant isocitrate dehydrogenases 1 and 2, and implicated in leukemogenesis (Proc Natl Acad Sci U S A 2013;110:17017–22).

The authors of the current study sought to explore alterations of glucose metabolism in AML and how they relate to clinical outcomes. A metabolomic analysis of serum using mass spectrometry and focusing on glucose metabolism was performed on samples that were collected from 229 patients at diagnosis of de novo AML and from 260 healthy controls. Among the 100 metabolites of glucose metabolism that were identified, six (lactate, 2-oxoglutarate, pyruvate, 2-HG, glycerol-3-phosphate, and citrate) were differentially expressed in sera from patients with AML compared with healthy controls, in the initial cohort as well as in a validation set.

Return to top

RELATED ARTICLES

Immunotherapy for Myeloid Leukemia
Marays Veliz, MD, and Javier Pinilla-Ibarz, MD

CML Leukemia and Lymphoma
Acute Leukemia
CML Leukemia and Lymphoma
Acute Leukemia
CML Leukemia and Lymphoma
Chronic Leukemia
CML Leukemia and Lymphoma
The Molecular Pathogenesis of Acute Myeloid Leukemia
Kiran Tawana1, Csaba Bödör2, Jamie Cavenagh3, Michael Jenner1, and Jude Fitzgibbon1
CML Leukemia and Lymphoma

LATEST ARTICLES